Travere Therapeutics Inc. (TVTX)

Travere (TVTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants co...

SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX #igan--CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guideline...

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go...

Initiating coverage on Travere Therapeutics with a "Buy: rating, citing strong growth potential for its kidney drug Filspari (sparsentan). Company's Filspari is FDA-approved for IgAN, with Q2 2025 U.S...

Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...

I am upgrading Travere Therapeutics, Inc. to a Buy, as the FDA's decision not to hold an AdCom suggests a favorable path for Filspari in FSGS. Filspari's strong sales growth, improved financials, and ...

Shares of Travere Therapeutics shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug, Filspari.

SAN DIEGO--(BUSINESS WIRE)---- $TVTX #FSGS--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further ...